Skip to main content
. 2022 Feb 14;3(3):e143–e152. doi: 10.1016/S2666-7568(22)00009-5

Figure 1.

Figure 1

CONSORT diagram and cohort assembly

CCC19=COVID-19 and Cancer Consortium. *In-situ malignancy, precursor haematologic condition, benign haematologic condition, non-melanoma skin cancer, non-invasive malignancy, false-positive SARS-CoV-2 test, or non-CCC19 site. †Quality score ≥5.